Engagement 2.0 Forms of Consent for Data (re-)Use

Mild Cognitive Impairment Clinical Trial

— ENGAGE  

Official title:

Engagement 2.0 Forms of Consent for Data (re-)Use

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05229978
• Other study ID #: Engage 2.0
• Status: Completed
• Start date: August 17, 2022
• Est. completion date: February 1, 2023

Study information

• Verified date: May 2022
• Source: Universitair Ziekenhuis Brussel
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objective of this qualitative study is to create a better understanding of patients' mental model of health data engagement interfaces and tools (such as Dynamic Consent). The researchers will focus especially on those people who - plausibly - require adjusted communication particularities and interaction modalities due to a cognitive impairment stemming from a neurodegenerative disease. Taking into account the specific characteristics of patients with dementia, the goal of this study is to investigate how to communicate according to patients' personal skills and capabilities and identify both the proper support mechanisms for engagement 2.0 consent as well as feedback mechanisms (return of research results). Through a focus group & interview setup, this study will discern design requirements and propose design recommendations for the (future) development of health data engagement interfaces.

Description:

While unprecedented amounts of multimodal health data become increasingly available and their secondary use in clinical and (bio)medical research holds great promise, people's agency over this data is in contention. In the context of biobank research, patient-centered initiatives such as 'dynamic consent' have been proposed as a way to provide people with ownership over their health data by allowing for granular expression of their consent preferences using a digital interface. Although such interfaces have been positively assessed within their original biobank context, more heterogeneous audiences will need to be considered if such a socio-technical tool is to be adopted widely and provide people ownership over their electronic medical records. One subset of people that will require adjusted functionalities and interaction modalities in this regard are those with a cognitive impairing condition like dementia, given the illness' consequences on decision making capacity. This study qualitatively explores the user & social requirements of a tool like dynamic consent if it is to be used in a meaningful way also by people with dementia and their (informal) carers. We report findings from interviews and an expert focus group with people with dementia, their caretakers, and experts to depict their views and requirements on a tool like dynamic consent.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: February 1, 2023
• Est. primary completion date: December 22, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• no diagnosed cognitive impairment but first-degree relative with AD

• mild cognitive impairment due to AD (diagnosed according to the NIA/AA diagnostic criteria)

• mild dementia due to AD (diagnosed according to the NIA/AA diagnostic criteria)

Exclusion Criteria:

• Patients with moderate to severe dementia due to AD, defined as MMSE total score 20/30 or lower

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer Disease, Early Onset
• Cognitive Dysfunction
• Mild Cognitive Impairment

Intervention

Other:
• Showing an existing Dynamic Consent (computer interface) as prompt
An existing Dynamic Consent interface will be shown as a prompt halfway through the focus group sessions.

Locations

Country	Name	City	State
Belgium	Universitair Ziekenhuis Brussel (UZB)	Jette	Brussel

Sponsors (1)

Lead Sponsor	Collaborator
Universitair Ziekenhuis Brussel

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Qualitative data: interpretations / opinions / needs / thoughts / feelings with regard to clinical data usage and dynamic consent.	Collected in response to questions from an open-ended questionnaire (interview guide), the outcome of the focus groups and interviews will be rich qualitative data that will provide a better understanding of patients' assumed skills, capabilities and preferences necessary to meaningfully interact with health data engagement (dynamic consent) interfaces" for clinical data usage consent.	1-2 months. During the focus groups and interviews, answers given by participants will be audiorecorded and later transcribed to be thematically analysed.